Viral Profiling Identifies Multiple Subtypes of Kaposi’s Sarcoma

Mina C. Hosseinipour,a,b,c Kristen M. Sweet,d Jie Xiong,e,f Dan Namarika,f Albert Mwafongo,g Michael Nyirenda,h Michael M. Kamwendo,h,i Ivan Hoffman,a,b Jeannette Lee, h,i Sam Phiri,i Wolfgang Vahrson,j Blossom Damania,c,d,f,g Dirk P. Dittmer,c,d,f

Center for Infectious Diseases and Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; UNC Project, Lilongwe, Malawi; Program in Global Oncology, Lineberger Comprehensive Cancer Center and Center for AIDS Research (CFAR); Department of Microbiology and Immunology, Curriculum in Genetics,a,b and Department of Statistics and Operations Research,a University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Kamuzu Central Hospital, Lilongwe, Malawi; Lighthouse Trust, Lilongwe, Malawi; University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA; AIDS Malignancy Consortium (AMC); Genedata, Basel, Switzerland

M.C.H. and K.M.S. contributed equally to this work.

ABSTRACT Kaposi’s sarcoma (KS), caused by KS-associated herpesvirus (KSHV), is the most common cancer among HIV-infected patients in Malawi and in the United States today. In Malawi, KSHV is endemic. We conducted a cross-sectional study of patients with HIV infection and KS with no history of chemotherapy or antiretroviral therapy (ART). Seventy patients were enrolled. Eighty-one percent had T1 (advanced) KS. Median CD4 and HIV RNA levels were 181 cells/mm³ and 138,641 copies/ml, respectively. We had complete information and suitable plasma and biopsy samples for 66 patients. For 59/66 (89%) patients, a detectable KSHV load was found in plasma (median, 2,291 copies/ml; interquartile range [IQR], 741 to 5,623). We utilized a novel KSHV real-time quantitative PCR (qPCR) array with multiple primers per open reading frame to examine KSHV transcription. Seventeen samples exhibited only minimal levels of KSHV mRNAs, presumably due to the limited number of infected cells. For all other biopsy samples, the viral latency locus (LANA, vCyc, vFLIP, kaposin, and microRNAs [miRNAs]) was transcribed abundantly, as was K15 mRNA. We could identify two subtypes of treatment-naïve KS: lesions that transcribed viral RNAs across the length of the viral genome and lesions that displayed only limited transcription restricted to the latency locus. This finding underpins for the first time the existence of multiple subtypes of KS lesions in HIV- and KS-treatment-naïve patients.

IMPORTANCE KS is the leading cancer in people infected with HIV worldwide and is causally linked to KSHV infection. Using viral transcription profiling, we have demonstrated the existence of multiple subtypes of KS lesions for the first time in HIV- and KS-treatment-naïve patients. A substantial number of lesions transcribe miRNAs which encode the viral kinases and hence could be targeted by the antiviral drugs ganciclovir or AZT in addition to chemotherapy.
presence of KHSV is required for KS tumorigenesis. KHSV is a human gammaherpesvirus that encodes more than 84 proteins that mediate viral replication and virus-host interactions (reviewed in reference 16). Theoretically, all KHSV proteins can be considered potential therapeutic targets. The viral proteins are expressed only in the tumor cells and probably also in preneoplastic cells, which form the latent reservoir that can progress to tumor cells. Two viral proteins that exhibit kinase activity are the viral thymidine kinase Orf21 and the viral protein kinase Orf36. These proteins have been shown to convert antiherpesvirus drugs, specifically ganciclovir, into their functional, toxic forms (17). Ganciclovir inhibits KHSV viral replication (18–21) and at high concentrations can inhibit tumor growth (17, 22–24).

The clinical experience of antiherpesvirus drugs in KS has yielded mixed results. We believe that this was in part because patients were enrolled without knowing if their lesions expressed the viral kinases (25–28). Knowing whether and which lesions express the viral kinases represents a gap in our current understanding. Increased understanding of KHSV gene expression in different types of KS may lead to patient intervention and stratification as a form of “personalized” KS therapy.

We found that treatment-naive AIDS-KS lesions differed significantly in their degree of KHSV transcription, allowing for a stratification of AIDS-KS cases according to the degree of so-called “lytic” gene expression. Such molecular biomarker-based division may be useful in optimizing treatment for KS patients. Previous studies evaluating this principle were small. Our group has prior experience in KHSV profiling of primary KS tissue. Those prior studies were based on archival samples from HIV-infected AIDS patients in the United States, which were heavily pretreated with chemotherapy, ART, or both (29, 30). To expand our understanding of KHSV gene expression, we conducted a cross-sectional study of 70 ART- and chemotherapy treatment-naive KS patients attending the Lighthouse (LH) clinic in Lilongwe, Malawi. We describe the KHSV viral load and KHSV mRNA transcription pattern in KS lesions from these patients so as to develop novel stratification methods that may provide prognostic and/or predictive information.

RESULTS

Study population and clinical characterization. From November 2008 through August 2010, we screened 217 HIV-infected KS patients. Seventy (32%) of the screened patients were eligible and enrolled in the profiling project. Fifty percent of patients were enrolled in the first 100 days, attesting to the high prevalence of KS in Malawi (see Fig. S1 in the supplemental material). Primary reasons for exclusion included previous use of ART (26%), chemotherapy (9.5%), or both (48%) and disease restricted to the oral cavity (5.5%). In total, 105 patients were excluded. Among enrolled clients, 71% were male. The median (interquartile range [IQR]) age, body mass index (BMI), CD4 level, and HIV RNA level were 32 years (29 to 38), 22.4 kg/m² (20.5 to 24.3), 181 cells/mm³ (85 to 261), and 138,641 copies/ml (54,900 to 285,000), respectively. Eighty-one percent presented with T1 (poor-risk) KS. Fifteen (22%) patients had 1 to 10 KS lesions, 42 (60%) patients had 10 to 50 lesions, and 12 (17%) patients had more than 50 lesions. Thirty-two (46%) patients had edema, 6 (9%) had concurrent oral KS, and 4 (6%) showed evidence of visceral KS (because of the absence of computed tomography scans, we cannot exclude that more of the patients had visceral KS) (see Table S1).

KHSV load did not correlate with CD4 count or HIV load. We observed no significant correlation between the log HIV load and CD4 counts per microliter (Fig. 1A). We observed no significant correlation between log KHSV load and disease stage (limited KS [T0] versus T1) or any other clinical parameters by multivariate linear regression. We chose to measure cell-free KHSV load rather than KHSV DNA in peripheral blood mononuclear cells (PBMC), since this is directly related to viral replication. The median plasma KHSV DNA load was 3.36 log copies (IQR, 2.87 to 3.75). In 7/66 (11%) samples, the KHSV load was below our limit of detection (200 copies/ml) even though we could detect KHSV mRNA in biopsy specimens from 6 of these 7 patients. Since we were able to amplify the internal control in these serum samples, they represent cases of clinically apparent KS in the absence of detectable systemic KHSV viral load.

After excluding the 7 samples with a KHSV load below the limit of detection, the log_{10} KHSV load and log_{10} HIV load were normally distributed (Fig. 1C and D). Since the CD4 count was not normally distributed, (Fig. 1E), we used square-root-transformed CD4 counts for all subsequent analyses. We observed no correlation between the log_{10} KHSV load and log_{10} HIV load or between the log_{10} KHSV load and square-root-transformed CD4 count. Three patients (triangles in Fig. 1B) had a CD4 count of >600 cells per microliter, high HIV load, and substantial KHSV loads in plasma at the same time. Overall, our data demonstrate that the KHSV load, HIV load, and CD4 counts are independent of each other in therapy-naive, HIV+ KS patients in regions to which KHSV is endemic.

Two subtypes of KS. One aim of this research was to determine whether molecular profiling of KHSV transcription in a suspected lesion was feasible and could provide an alternative to traditional pathology in resource-limited settings. We found RNAlater to be a suitable fixation and transport medium at tropical room temperature. Figure 2A describes the data analysis plan. First, we excluded any cases with incomplete clinical data. Five out of 66 (8%) biopsy specimens had “housekeeping” mRNAs with abnormally low levels (threshold cycle C_T > 32), suggestive of RNA degradation. These samples were excluded from further analysis. We could not detect the mRNA for the KHSV latent genes in 10 biopsy specimens for which we could detect “housekeeping” mRNAs. This suggests that very few cells in the lesions were infected or that the level of latent gene expression per cell was minimal. Nine of these ten patients had a detectable KHSV load in plasma and multiple KS lesions. We cannot exclude that the wrong lesions or a highly fibrous or necrotic lesion was biopsied. These 10 samples were therefore excluded from further analysis. To arrive at the final high quality data set, we removed additional samples, which had KHSV latent mRNA levels that were detectable but much lower than the mean of the set. This provided us with 48 high-quality samples, which were split into a discovery set and a validation set. These samples were run on different days and with different lots of reagents, i.e., as true experimental replicates. We used a new, second-generation real-time quantitative PCR (qPCR) array consisting of 188 individual qPCR primer pairs (see Fig. S2 in the supplemental material).

Figure 2B shows the density curves for 12 samples from the discovery set, i.e., the fraction of primers with indicated cycle number C_T. A higher C_T corresponds to lower mRNA abundance. The housekeeping mRNAs (blue) were more abundant and similar across all samples than the viral mRNAs (red). Two “bulges”
were observed for the “housekeeping” mRNAs, representing highly abundant (C<sub>T</sub> < 30; actin, gapdh, and β2m) and less abundant (C<sub>T</sub> > 30; hprt) “housekeeping” mRNAs. In contrast, many viral mRNAs were undetectable, leading to the sharp peak at a C<sub>T</sub> of 45. A peak at C<sub>T</sub> 45 indicates the end of the PCR. Such a mRNA was not detectable, and no PCR product was formed. We could distinguish two subtypes of KS: samples with a significant peak at a C<sub>T</sub> 45, i.e., very limited viral transcription (yellow background), and samples with a lower peak at a C<sub>T</sub> of 45 and a significant, second “bulge” at a C<sub>T</sub> of <40, i.e., many viral mRNAs were detectable (gray background).

Figure 3 shows a heat map of viral transcription in the n = 35 sample validation set (a heat map of the discovery set is shown in Fig. S3 in the supplemental material; also provided, as Fig. S5, is a high-resolution image of Fig. 3). This unsupervised approach uncovered two subtypes: a and b. Subtype a contained biopsy specimens with a highly restricted, latent pattern of KSHV transcription; subtype b contained biopsy specimens with a more extended pattern of KSHV transcription. Note that mRNAs with marginal mean expression or those which did not change across samples were trimmed prior to clustering. The KSHV primer pairs (and underlying mRNA levels) fell into 3 different clusters. Note that both the overall levels and the pattern of transcription influence cluster membership. The ordering within any cluster was not significant. Whereas the samples could be divided into two subtypes, a and b, the various KSHV mRNAs, as measured by real-time qPCR primer pairs, could be divided into multiple classes or clusters, labeled i, ii, and iii. Members of cluster i were highly expressed in many samples. Members of cluster ii were expressed at high levels in only a few samples. Members of cluster iii were expressed at low levels in only a few samples. KSHV mRNA classes are further analyzed using more accurate methods detailed below.

In sum, on the basis of unsupervised hierarchical clustering, KS lesions could be divided into two subtypes: those with limited viral gene transcription and those with evidence for widespread KSHV gene transcription.

**KSHV mRNA patterns in KS.** We are confident about the existence of different subtypes of KS, because the number of variables, i.e., primer pairs (n = 188), exceeded the number of samples (n = 35). Independent corroboration using principal-component analysis (PCA) and analysis of normalization methods is presented in Fig. S4 in the supplemental material. Identifying clusters of differentially regulated viral mRNAs was much more challenging, because here the design was underpowered. Ideally, one would like to have as many samples as genes. This would require 188 biopsy specimens. We attempted to identify mRNAs that differ among the KS subtypes and thus may be developed into prognostic and/or predictive biomarker signatures by making the assumption that latency locus mRNAs do not change in levels and could therefore be used to normalize all data (ddC<sub>T</sub>) (30). This also normalizes for tumor cell content per sample, since all KS tumor cells and only the KS tumor cells transcribe viral latent mRNAs, as previously shown by in situ methods (31, 32). Figure 4A shows the relative expression (ddC<sub>T</sub>) at each position on the genome. Red indicates members of cluster b, i.e., biopsy specimens with evidence of extended viral transcription, and blue indicates members of cluster a, i.e., biopsy specimens with limited transcription.

Due to the fact that poly(A) mRNA was isolated from the tumor samples in order to increase sensitivity and to decrease back-
ground due to residual DNA, we noticed a poly(A) site position effect: the signal for the vFLIP primers, which are located proximal to the poly(A) site for the tricistronic LANA/vCYC/vFLIP latency mRNA (as well as the bicistronic vCYC/vFLIP mRNA), yielded a higher signal than the more distal vCYC and LANA primers. Likewise, the most poly(A)-site-proximal vGPCR primers yielded a higher signal than the more distally located K14 primers, even though both measure the same mRNA. This did not affect the comparison between samples, however, since those comparisons were done on a primer-by-primer basis.

Next, we averaged all primer pairs located within the same Orf together (Fig. 4B). Again, red indicates biopsy specimens with evidence for extended KSHV transcription, and blue indicates biopsy specimens with limited KSHV transcription. For some genes, e.g., K3 and K4, no mRNA was detectable in the latent KS subtypes. For most KSHV genes, e.g., Orf10 and Orf6, mRNA levels were significantly higher in the “extended” transcription cluster (red) than in the tightly latent cluster (blue). Orf58 represents an example of an mRNA with consistently high levels in the “extended” transcription subtype, as indicated by the short red bar, and extremely variable mRNA levels within the “latent” subtype, as indicated by the very long blue bar. K15 represents an example of an mRNA with consistently variable expression in both KS subtypes. In the case of K1 and K15, some of the variability may be due to strain differences, since these two genes are highly polymorphic.

The large number of samples and primers allowed us to test the hypothesis that transcription differed for specific orfs among the subtypes (Fig. 4C). To adjust for multiple comparisons, we controlled the false discovery rate to a significance level of 0.05. Figure 4E shows that approximately 30 KSHV mRNAs differed significantly between the two KS subtypes (also see Table S2). Figure 4F shows that among the top 30 differently regulated KSHV mRNAs, we would expect no more than 2 false-positive results. Table S2 lists these mRNAs.

In sum, using multiple analytical approaches, more than 180 individual markers, and two independent biological data sets, we established the existence of at least two KS subtypes in chemotherapy- and ART treatment-naive KS lesions. Potentially, up to 30 KSHV genes could be developed into either individual biomarkers or a composite biomarker signature for the purpose of prognosis and treatment stratification of KS prior to therapy.

### DISCUSSION

Advances in molecular profiling and in histopathology have taught us the value of tumor subtyping and stratification in understanding pathology and designing better treatment regimens, as has been seen, e.g., in breast cancer. The same rationale applies to KS. Clinicians have long distinguished plaque, patch, and nodular KS lesions. Pathologists have long distinguished plaque, patch, and nodular histological stages (33, 34), though the histology does not always correspond to the clinical notation.

For HIV+ KS patients, ART represents first-line therapy since ART alone can lead to the resolution of KS in some patients. It is unclear, however, which KS patients respond to ART alone, which KS patients benefit from immediate, ART-concurrent chemotherapy, and which KS patients benefit from ART-concurrent, anti-KSHV therapy (ganciclovir, valganciclovir, and cidofovir) (10, 33, 34).
Some patients, particularly in regions to which KS is endemic, respond to ART initiation with exaggerated disease, termed KS immune reconstitution syndrome (KS-IRIS) (11–14).

The current KS staging is based on immune status (CD4 count), KS disease stage, and systemic involvement (T0, T1) (38). In the post-ART era, CD4 count may no longer provide prognostic information (39). It is unclear whether the same KS staging criteria that were developed in the United States and Europe during the initial phase of the AIDS epidemic, where KSHV was acquired late in life and predominantly by sexual contact (40, 41), also apply to KS that develops in HIV+ patients in areas of KSHV endemicity, where KSHV is often acquired before the onset of sexual maturity.

We observed only marginal correlations between extents of disease, systemic KSHV load, HIV load, and CD4 counts. In the post-ART era, approximately 30% of KS in the United States manifested itself in long-term ART-controlled individuals (9, 42, 43) with no detectable HIV load and >250 CD4 cells/µL. An implication of this study is that in areas to which KS is endemic, KS disease is observed in the setting of low as well as moderate CD4 counts (>250 CD4 cells/µL). Cases of extensive KS, despite high CD4 counts, were also seen in an ART-naive South African cohort (44) and in Uganda (38). This may be a unique feature of AIDS-KS in regions of KSHV endemicity.

The diagnosis of KS is a challenge in areas where pathology is limited. A molecular assay would greatly improve diagnosis. We observed 7 cases of KS with no detectable systemic KSHV load. For 6 of these patients, the KS lesions nevertheless tested positive for KSHV mRNA. Others also failed to detect KSHV in blood in as many as 25% of patients (45, 46). Thus, detecting KSHV mRNA in lesions may improve diagnosis. An advantage of molecular assays, particularly if they can be developed into robust point-of-care assays, is that they obviate the need for evaluation by pathologists, who are not affordable or not present in many low- and middle-income countries.

We previously demonstrated that lesions from advanced AIDS-KS cases from the pre-ART era and KS that developed in HIV-suppressed individuals on successful ART separated into two groups based on their KSHV transcription profiles (29, 30). Evidence of “extended” KS kinase transcription was virtually absent in classic KS, where ganciclovir monotherapy did not induce KS regression (25). These earlier studies were limited in size and comprised of groups of heavily pretreated patients. Those limitations were overcome in the current study, which involved only treatment-naive patients. Here, we identified multiple subtypes of KS transcriptional signatures. Half the samples exhibited a “latent” transcription pattern, which was limited to transcripts across the KSHV latency locus (LANA/vCyc/vFLIP/miRNAs).

Figure Legend Continued
indicates no or low signal for a given primer pair on the vertical axis. Each PCR primer pair is named on the left and coded by the Orf name and forward primer position. The green overlay indicates mRNAs that originate in the KSHV latency region, and the yellow overlay highlights primer pairs that detect expression of the KSHV K14/vGPCR transcript. The dendrogram on top showing clustering of KS biopsy specimens indicates two clusters of samples, a and b. Sample, i.e., biopsy specimen identities are listed on the bottom. The larger number of samples allowed for more detailed clustering of KSHV transcription. Three clusters of KSHV transcripts could be identified, and those are labeled on the right as i, ii, and iii. A high-resolution figure with exact primer locations can be found in the supplemental material.
This kind of transcription predominates in primary effusion lymphoma (PEL) grown in culture (47), as well as most latently KSHV-infected endothelial cells (48). The other half of samples exhibited extended but incomplete viral transcription. The mRNAs of known signaling/pathogenesis molecules, such as K1, K15, and some of the viral interferon regulatory factors (vIRFs), were detectable, as were mRNAs encoding Orf21/thymidine kinase and Orf36/protein kinase. Similar “extended” transcription has been observed in PEL xenografts (49), in some PEL with substantial rates of spontaneous lytic reactivation (50), and other KSHV-infected endothelial cells (51–53). Other studies now also find extended viral transcripts under conditions of incomplete/abortive gammaherpesvirus replication (50, 54, 55).

Only one of the samples exhibited a complete (within the sensitivity of detection) lytic transcription profile, as would be seen in virus-producing cell lines (47, 56, 57). For this cross-sectional study, we do not have follow-up data on the patients and thus cannot directly assess the prognostic or predictive value of transcription.

FIG 4 Analysis of individual KSHV transcripts across two KS subtypes in the validation set (n = 35). (A) Dot plot of the ddCT values on the vertical axis versus KSHV genome position on the horizontal axis. The ddCT values were obtained by first normalizing to the geometric mean of a set of “housekeeping mRNAs” and then the level of vFLIP mRNA (indicated at ddCT = 0). Red indicates samples from the “expanded” subtype, and blue indicates samples from the “restricted” KS subtype. All samples with a ddCT value of ≤−20 were set to ddCT = −20 and considered background. (B) Box plot of the ddCT values on the vertical axis versus KSHV Orf on the horizontal axis. All primers within the same Orf were averaged to give the “white” median value. The extent of the box indicates the 25th to 75th percentiles of the data. Outliers are not shown. Red indicates samples from the “expanded” subtype, and blue indicates samples from the “restricted” KS subtype. The vFLIP measurements used for normalization are shown on the far right. (C) P value distribution of Wilcoxon nonparametric comparison of relative mRNA levels by Orf between “red” and “blue” KS subtypes. (D) q value distribution, which represents adjustment for multiple comparison. A significance level of log(q) < 1.5, i.e., q < 0.03, is shown. (E) Distribution of the expected number of significant tests at a given q value cutoff. (F) Distribution of the expected number of false-positive comparisons based on the number of significant tests. Table S2 lists these mRNAs.
scritural profiling. Two larger clinical trials, A5263/AMC066 for advanced (T1) KS and A5264/AMC067 for limited (T0) KS, are currently enrolling patients across sub-Saharan Africa. These trials will also profile KS transcription and will allow us to correlate the molecular profile to disease progression and treatment responses. Even this limited cohort suggests that ART-naive KS patients may benefit from antitherpesvirus therapy in addition to ART and/or anticancer therapy and that these benefits would be most pronounced if patients were stratified based on transcriptional profiling of KS biopsy specimens.

MATERIALS AND METHODS

Study setting. The Lighthouse (LH) ART clinic at Kamuzu Central Hospital serves as the Center of Excellence for the Central Region of Malawi. In addition to providing primary care and general ART services for 20,000 ART clients according to Malawi ART guidelines, the LH provides specialized services for referred cases, including combination chemotherapy for KS, evaluation of severe toxicities and ART treatment failure, and modification of ART for second line and nonstandard regimens. All services at LH are provided for free.

Design and participants. A cross-sectional study was designed. All adult (age ≥18 years) KS patients presenting to the LH clinic between November 2008 and August 2010 were evaluated for potential enrollment. Patients with prior chemotherapy or antiretroviral therapy use were excluded, as were individuals with disease limited to the oral cavity (due to an inability to safely biopsy such lesions in the clinical setting).

Clinical procedures. KS clinical staging was performed according to AIDS Clinical Trials Group (ACTG) criteria (T1, advanced stage, versus T0, limited disease); blood was obtained for CD4 cell count and KSHV quantification, and a punch biopsy was performed for evaluation of viral transcription. The 2- by 2-mm punch biopsy samples were immersed in RNAlater (Ambion Inc.) due to its suitability for collection at the bedside, local storage, intercontinental transport (samples could be shipped at room temperature), and automated RNA isolation.

Clinical laboratory procedures. CD4 counts and HIV RNA determination were performed in real time at the UNC Project laboratory using a FACScount system and Roche Amplicor assay 1.5. KSHV DNA was isolated using the MagnaPure system (Roche Inc.). The KSHV load was determined in plasma DNA by real-time qPCR as described, using the LANA78 primers (5'-GGAAGGGCCATAATCTTGC and 5'-GCGCTCAGGGCAGG) and SYBR green (Roche Inc.) as the method of detection.

Real-time qPCR profiling. KSHV mRNA levels were determined in batch at the UNC—Chapel Hill Vironomics Core as per our published procedures (30, 58). These are available at http://www.med .unc.edu/vironomics/protocols.

Statistical analysis. We performed basic descriptive statistics with bi-variable comparisons according to ACTG tumor status using χ² methodology or Student’s t test as appropriate. Further statistical analysis was performed using the software environment R, version 2.15.1, as indicated in Text S1 (Methods) in the supplemental material.

Ethics. The study was IRB approved in Malawi and at the University of North Carolina (UNC) (IRB no. 08-0567) as “AMC-S001: CID 0802—a pilot study of Kaposi sarcoma-associated herpesvirus (KSHV) gene expression in patients with newly diagnosed Kaposi sarcoma (KS) in Malawi.” All subjects provided written informed consent.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at http://mbio.asm.org /lookup/suppl/doi:10.1128/mBio.01633-14/-/DCSupplemental.

Figure S1, TIF file, 0.2 MB. Figure S2, TIF file, 0.8 MB. Figure S3, TIF file, 1.4 MB. Figure S4, TIF file, 0.8 MB. Figure S5, TIF file, 1.6 MB.

Table S1, DOCX file, 0.01 MB. Table S2, DOCX file, 0.1 MB. Data Set S1, PDF file, 0.1 MB. Text S1, DOCX file, 0.2 MB.

ACKNOWLEDGMENTS

This study was supported by the AIDS Malignancy Clinical Trials Consortium (CA121947), NCI supplement to the UNC Lineberger Comprehensive Cancer Center (CA016086), the UNC Center for AIDS Research (AI050410), and NIH grants CA109232 and CA109104 to D.D. and CA096500, AI107810, and DE023940 to B.D. K.T. was supported by T32 GM07092-34 and by a grant to the University of North Carolina at Chapel Hill from Howard Hughes Medical Institute (HHMI) through the Med into Grad Initiative.

REFERENCES

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J. Clin. 61:69–90. http://dx.doi.org/10.3322/ ccac.201107

2. Semeere AS, Busakhaba N, Martin JR. 2012. Impact of antiretroviral therapy on the incidence of Kaposi’s sarcoma in resource-rich and resource-limited settings. Curr. Opin. Oncol. 24:522–530. http:// dx.doi.org/10.1097/CCO.0b013e328349428d

3. Gopal S, Achenbach CJ, Yanik EL, Dittmer DP, Eron JJ, Engels EA. 2014. Moving forward in HIV-associated cancer. J. Clin. Oncol. 32:876–880. http://dx.doi.org/10.1200/JCO.2013.53.1376.

4. Yanik EL, Napravnik S, Cole SR, Achenbach CJ, Gopal S, Olshan A, Dittmer DP, Kitahata MM, Mugavero MJ, Saag M, Moore RD, Mayer K, Mathews WC, Hunt PW, Rodriguez B, Eron JJ. 2013. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin. Infect. Dis. 57:756–764. http://dx.doi.org/10.1093/cid/cis609.

5. Yanik EL, Tamburro K, Eron JJ, Damania B, Napravnik S, Dittmer DP. 2013. Recent cancer incidence trends in an observational clinical cohort of HIV-infected patients in the US, 2000–2011. Infect. Agents Cancer. 8:18. http://dx.doi.org/10.1186/1750-9378-8-18.

6. Shids MS, Pfeiffer RM, Hall HI, Li J, Goedert JJ, Morton LM, Hartge P, Engels EA. 2011. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980–2007. JAMA 305:1450–1459. http://dx.doi.org/10.1001/jama.2011.396.

7. Dittmer DP, Richards KL, Damania B. 2012. Treatment of Kaposi sarcoma-associated herpesvirus-associated cancers. Front. Microbiol. 3:141. http://dx.doi.org/10.3389/fmicb.2012.00141.

8. Krown SE. 2011. Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: challenges and opportunities. Curr. Opin. Oncol. 23:463–468. http://dx.doi.org/10.1097/CCO.0b013e328349428d.

9. Krown SE, Lee JY, Dittmer DP, AIDS Malignancy Consor- tum. 2008. More on HIV-associated Kaposi’s sarcoma. N. Engl. J. Med. 358:535–536; author reply, 536. http://dx.doi.org/10.1056/NEJM072994.

10. Nguyen HQ, Magaret AS, Kitahata MM, Van Rompuye SE, Wald A, Casper C. 2008. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 22:937–945. http://dx.doi.org/10.1097/QAD.0b013e3282f2f275.

11. Cox CM, El-Mallawany NK, Kabue M, Kovarik C, Schutze GE, Kazembe PN, Mehta PS. 2013. Clinical characteristics and outcomes of HIV-infected children diagnosed with Kaposi sarcoma in Malawi and Botswana. Pediatr. Blood Cancer 60:1274–1280. http://dx.doi.org/10.1002/ pbc.24516.

12. Letang E, Lewis JJ, Bower M, Mosam A, Borok M, Campbell TB, Naniche D, Newsom-Davis T, Shaik F, Fiorillo S, Miro JM, Schellenberg D, Easterbrook PJ. 2013. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS 27:1603–1613. http://dx.doi.org/10.1097/ QAD.0b013e32836ea5a1.

13. Achenbach CJ, Harrington RD, Dhanireddy S, Crane HM, Casper C, Kitahata MM. 2012. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin. Infect. Dis. 54:424–433. http://dx.doi.org/10.1093/cid/cir802.

14. Bower M, Nelson M, Young AM, Thirlwell C, Newsom-Davis T, Man-

September/October 2014 Volume 5 Issue 5 e01633-14
A cluster of latently expressed genes in Kaposi’s sarcoma-associated herpesvirus. J. Virol. 72:8309–8315.

33. Pantanowitz L, Otis CN, Dezube BJ. 2010. Immunohistochemistry in Kaposi’s sarcoma. Clin. Exp. Dermatol. 35:68–72. http://dx.doi.org/10.1111/j.1365-2220.2009.03507.x.

34. Dittmer DP, Brandstetter EM, Bracken M. 1992. Kaposi’s sarcoma: a review of gene expression and ultrastructure of KS spindle cells in vivo. AIDS Res. Hum. Retroviruses 8:1753–1763. http://dx.doi.org/10.1089/aid.1992.8.1753.

35. Borok M, Fiorillo S, Godza I, Putnam B, Ndemera B, White IE, Gwanzura L, Schooley RT, Campbell TB. 2010. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. Clin. Infect. Dis. 51:342–349. http://dx.doi.org/10.1086/654800.

36. Mosam A, Shaik F, Uldrick TS, Esterhuizen T, Friedland GH, Scadden DT, Aboobaker J, Coovadia HM. 2012. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J. Acquir. Immune Defic. Syndr. 60:150–157. http://dx.doi.org/10.1097/QAI.0b013e318251aedd.

37. Bihl F, Mosam A, Henry LN, Chisholm JV, III, Dollard S, Gumbi P, Cassol E, Page T, Mueller N, Kiepiela P, Martin JN, Coovadia HM, Scadden DT, Brander C. 2007. Kaposi’s sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi’s sarcoma. AIDS 21:1425–14252. http://dx.doi.org/10.1097/QAD.0b013e32812fd803.

38. Jonston C, Oren J, Okulik F, Kalinski M, Saracino M, Kattula S, Llombart-Bosch A, Mbide E, Sande M, Ronald A, McAdam K, Huang ML, Drolette D, Selke S, Wald A, Corey L, Casper C. 2009. Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda. PLoS One 4:e4222. http://dx.doi.org/10.1371/journal.pone.0004222.

39. Nasti G, Marrellotta F, Berretta M, Mena M, Fasan M, Di Perri G, Tulpule A, Dezube BJ, Alboofaia DM, Ambinder RF. 1999. Sexual transmission and the natural history of human herpesvirus-8 infection. N. Engl. J. Med. 338:948–954. http://dx.doi.org/10.1056/NEJM199802203381403.

40. Martin JN, Gamen DE, Osmond DH, Page-Shaffer KA, Macrae D, Kedes DH. 1998. Sexual transmission and the natural history of human herpesvirus 8 infection. N. Engl. J. Med. 338:948–954. http://dx.doi.org/10.1056/NEJM199802203381403.

41. Butler LM, Dorsey G, Hladik W, Rosenthal PJ, Brander C, Neilands TB, Mbisa G, Whithy D, Kiepiela P, Mosam A, Mzolo S, Dollard SC, Martin JN. 2009. Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission. J. Infect. Dis. 200:430–438. http://dx.doi.org/10.1086/651003.

42. Maurer T, Ponte M, Leslie K. 2007. HIV-associated Kaposi’s sarcoma with a high CD4 count and a low viral load. N. Engl. J. Med. 357:1352–1353. http://dx.doi.org/10.1056/NEJMoa070508.

43. Gianfrasca M, Lee S, Von Roenn J, Tulipate A, Dezube BJ, Aboulafia DM, Ambinder RF, Lee JY, Krown SE, Sparano JA. 2010. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 116:3969–3977. http://dx.doi.org/10.1002/cncr.25362.

44. Cassol E, Page T, Mosam A, Friedland G, Jack C, Laloo U, Kopetka J, Patterson B, Esterhuizen T, Coovadia HM. 2005. Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8. J. Infect. Dis. 191:324–332. http://dx.doi.org/10.1086/427337.

45. Martin-Carbonero L, Palacios R, Valencia E, Saballs P, Martin JN, Cordoba R. 2008. Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8. J. Infect. Dis. 191:324–332. http://dx.doi.org/10.1086/427337.

46. Bower M, Dalla Pria A, Cynque A, Ennies E, Tittle V, Dhoot S, Nelson M. 2014. Prospective stage-stratified approach to AIDS-related Kaposi’s sarcoma. J. Clin. Oncol. 32:409–414. http://dx.doi.org/10.1200/JCO.2013.31.6757.
47. Fakhari FD, Dittmer DP. 2002. Charting latency transcripts in Kaposi’s sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR. J. Virol. 76:6213–6223. http://dx.doi.org/10.1128/JVI.76.12.6213-6223.2002.
48. An FQ, Folarin HM, Compitello N, Roth J, Gerson SL, McCrae KR, Fakhari FD, Dittmer DP, Renne R. 2006. Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi’s sarcoma-associated herpesvirus latency in vitro and in vivo. J. Virol. 80:4833–4846. http://dx.doi.org/10.1128/JVI.80.10.4833-4846.2006.
49. Staudt MR, Kanan Y, Jeong JH, Papin JF, Hines-Boykin R, Dittmer DP. 2004. The tumor microenvironment controls primary effusion lymphoma growth in vivo. Cancer Res. 64:4790–4799. http://dx.doi.org/10.1158/0008-5472.CAN-03-3835.
50. Chandriani S, Ganem D. 2010. Array-based transcript profiling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposi’s sarcoma-associated herpesvirus. J. Virol. 84:5565–5573. http://dx.doi.org/10.1128/JVI.02723-09.
51. Chang HH, Ganem D. 2013. A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity. Cell Host Microbe 13:429–440. http://dx.doi.org/10.1016/j.chom.2013.03.009.
52. Wang L, Dittmer DP, Tomlinson CC, Fakhari FD, Damania B. 2006. Immortalization of primary endothelial cells by the K1 protein of Kaposi’s sarcoma-associated herpesvirus. Cancer Res. 66:3658–3666. http://dx.doi.org/10.1158/0008-5472.CAN-05-3680.
53. Mutlu AD, Cavallin LE, Vincent L, Chiozzini C, Eroles P, Duran EM, Asgari Z, Hooper AT, La Perle KM, Hilshier C, Gao SJ, Dittmer DP, Rafii S, Mesri EA. 2007. In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi’s sarcoma. Cancer Cell 11:245–258. http://dx.doi.org/10.1016/j.ccr.2007.01.015.
54. Arias C, Weisburd B, Stern-Ginossar N, Mercier A, Madrid AS, Bellare P, Holdorf M, Weissman JS, Ganem D. 2014. KSHV 2.0: a comprehensive annotation of the Kaposi’s sarcoma-associated herpesvirus genome using next-generation sequencing reveals novel genomic and functional features. PLoS Pathog. 10:e1003847. http://dx.doi.org/10.1371/journal.ppat.1003847.
55. Canny SP, Reese TA, Johnson LS, Zhang X, Kambal A, Duan E, Liu CY, Virgin HW. 2014. Pervasive transcription of a herpesvirus genome generates functionally important RNAs. mBio 5(2):e01033-13. http://dx.doi.org/10.1128/mBio.01033-13.
56. Jenner RG, Albà MM, Boshoff C, Kellam P. 2001. Kaposi’s sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J. Virol. 75:891–902. http://dx.doi.org/10.1128/JVI.75.2.891-902.2001.
57. Paulose-Murphy M, Ha NK, Xiang C, Chen Y, Gillim L, Yarchoan R, Meltzer P, Bittner M, Trent J, Zeichner S. 2001. Transcription program of human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus). J. Virol. 75:4843–4853. http://dx.doi.org/10.1128/JVI.75.10.4843-4853.2001.
58. Papin J, Vahrson W, Hines-Boykin R, Dittmer DP. 2005. Real-time quantitative PCR analysis of viral transcription. Methods Mol. Biol. 292:449–480.